skip to Main Content

Phage display is a powerful technique to interrogate a vast array of molecules quickly and efficiently and rare binders can be selected using iterative rounds of panning.  Our extensive expertise, state-of-the-art technology and complex phage libraries (peptide and antibody), ensure we will identify strong leads for any drug discovery program.

We can screen receptors in vitro and cells both in vitro and in vivo to find the best candidates for your project, whether you are targeting protein-protein interactions, searching for co-agonists or developing anti-tumour antibodies.

IRBM’s integrated process provides seamless transition from library construction and selection to in vivo assessments. Vast libraries can be interrogated by affinity selection to identify rare and high affinity binders, and our automated screening, sequencing and confirmation workflows mean thousands of phage clones can be analysed quickly and efficiently.

To pursue binders that recognise the target under physiological conditions, we run affinity selection on cells in vitro and also in vivo. This creates opportunities for us to identify candidates that function in complex biological processes such as blood-brain barrier penetration.

Affinity maturation of antibodies is carried out using our affinity maturation library. When it comes to peptides, our specialist peptide chemistry team will optimise putative leads using an extensive range of modification and analytical techniques.

Together with our high complexity peptide and antibody libraries, we can also build focused libraries based on the known interaction surfaces between two proteins. With the crystal structure defined, we can generate a target-specific library, allowing us to increase the affinity of a lead to a target protein from micromolar to picomolar affinities within a few months.



Back To Top